The first CAR-T was priced at $475,000 and the second at $373,000. Whilst not the most expensive, these therapies offer life-changing treatment options and thus the affordability debate has to be balanced with the accessibility debate.
Attend this session to discuss:
Leave with a full understanding of the various pricing and reimbursement strategies and business models for CAR-T and TCR therapies and how we can ensure affordability and accessibility of these ground-breaking therapies.
Mark McCall, Centre for Biological Engineering, Loughborough University
Detlev Parow, Head, Care Management Development, DAK-Gesundheit
Grace Hampson, Senior Economist, The Office of Health Economics
With the next CAR-T approval set to come from the EMA, understanding the regulations from IND submission through to drug approval is important to ensure the success of your therapeutic.
Attend this session with the Chair of the CAT at the EMA to discuss:
Leave this session with the regulatory perspectives and guidelines for the development and approval of novel cell and gene immunotherapies.
Martina Schussler-Lenz, Chair CAT, EMA